Gene expression profiles of chimeric cytokine receptor-engineered CAR-T cells
RNA-seq (gene expression) · human · 12 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 12 samples: 3 × Control, IL6-, dono vs 3 × Control, IL6+, dono vs 3 × G6/7R, IL6-, dono vs 3 × G6/7R, IL6+, donoGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cellsCell reports. Medicine · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE216734_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA895069 and SRA study SRP404933. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 12 samples.
How we read this: 4 replicated groups read from 12 sample titles; they account for 12 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM6689677 Control, IL6-, donor 1 Control, IL6-, dono
- GSM6689678 Control, IL6+, donor 1 Control, IL6+, dono
- GSM6689679 Control, IL6-, donor 2 Control, IL6-, dono
- GSM6689680 Control, IL6+, donor 2 Control, IL6+, dono
- GSM6689681 Control, IL6-, donor 3 Control, IL6-, dono
- GSM6689682 Control, IL6+, donor 3 Control, IL6+, dono
- GSM6689683 G6/7R, IL6-, donor 1 G6/7R, IL6-, dono
- GSM6689684 G6/7R, IL6+, donor 1 G6/7R, IL6+, dono
- GSM6689685 G6/7R, IL6-, donor 2 G6/7R, IL6-, dono
- GSM6689686 G6/7R, IL6+, donor 2 G6/7R, IL6+, dono
- GSM6689687 G6/7R, IL6-, donor 3 G6/7R, IL6-, dono
- GSM6689688 G6/7R, IL6+, donor 3 G6/7R, IL6+, dono
- GSE328224 Reprogramming CAR with cytokine signaling increases the efficacy of CAR-T cell therapy in solid tumour treatment and confers sustained immune memory 11 samples shares car-t, cytokine
- GSE280810 Macrophages expressing chimeric cytokine receptors have an inflammatory phenotype and anti-tumoral activity upon IL-10 or TGFβ stimulation 30 samples shares chimeric, cytokine
- GSE297676 Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single cell RNA sequencing 57 samples shares car-t
- GSE322796 Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy 23 samples shares car-t
- GSE320375 On-demand GLUT3 expression augments CAR-T cell metabolic fitness and antitumor efficacy whereas preventing toxicity in glioblastoma 16 samples shares car-t
- GSE254546 RNA sequencing comparison of B7-H3.TMIGD2 and B7-H3.CD28.4-1BB CAR-T cells to CD19.CD28.4-1BB CAR-T cells in vitro 12 samples shares car-t
- GSE277818 Targeting PRC2 enhances the antitumor cytotoxic capacity of anti-CD19 CAR-T cells against hematological malignancies 12 samples shares car-t
- GSE267097 Pre-Treatment peripheral Immune composition can accurately predict CAR-T outcomes in patients with Large B-Cell Lymphoma 49 samples shares car-t
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.